Skip to main
  1. Stocks
  2. Nyxoah SA
  3. Forecast
NYXH

Nyxoah SA (NYXH) Stock Forecast & Price Target

Nyxoah SA (NYXH) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 0%
Buy 67%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Nyxoah is constructive fundamentally because its U.S. rollout continues to build through measurable operating momentum, with 80 additional trained surgeons, 53 activated accounts, 447 patients under active prior authorization, and a 29% sequential increase in U.S. growth, suggesting the recent revenue guide reset reflects timing rather than demand deterioration. The company also has a meaningful regulatory catalyst in motion, as it submitted its PMA supplement for CCC after ACCCESS met both co-primary efficacy endpoints with a 77.2% 12-month AHI responder rate and zero device- or procedure-related SAEs, which could expand the addressable OSA population by roughly 25-30%. Financially, Q2 net revenue of €7.7M was in line with expectations and FY26 guidance of €36-40M was reiterated, while Genio 2.1 approval, ongoing sales hiring, and the planned 2027 reimbursement pathway support a longer-term commercialization thesis.

Bears say

Nyxoah is facing a weakening fundamental setup after pre-announcing 3Q26 net revenue of €9.2M versus FactSet consensus of €9.9M and cutting full-year 2026 revenue guidance to €33-35M from €36-40M, signaling softer-than-expected commercialization momentum. The company still depends on a cash-burn-heavy model to scale its Genio system against the market leader Inspire Medical Systems, which leaves it vulnerable to adoption risk and the possibility of needing additional capital. In addition, regulatory uncertainty around the ACCCESS study and the fact that valuation still implies 1.9x 2027 EV/revenue and 2.8x 2028 EV/revenue, even at a 54% discount to peers, support a cautious outlook.

Nyxoah SA (NYXH) has been analyzed by 3 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 67% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nyxoah SA and is not a guaranteed prediction by Public.com or investment advice.

Nyxoah SA (NYXH) Analyst Forecast & Price Prediction

Get the latest Nyxoah SA (NYXH) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Nyxoah SA (NYXH)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nyxoah SA (NYXH) Forecast

Analysts have given Nyxoah SA (NYXH) a Buy based on their latest research and market trends.

According to 3 analysts, Nyxoah SA (NYXH) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nyxoah SA (NYXH)


Nyxoah SA (NYXH) Analyst Forecast & Price Prediction

Get the latest Nyxoah SA (NYXH) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Nyxoah SA (NYXH)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover NYXH stock data and trends